The TRICAV II clinical trial is to determine the safety and effectiveness of theTricValve® Transcatheter Bicaval System.
This trial is for patients with severe or greater tricuspid regurgitation.
*CAUTION : TricValve is an Investigational Device. Limited by Federal (United States) Law to Investigational Use.
Learn more about the TRICAV Trial at ClinicalTrials.gov.
Tricuspid regurgitation (TR) occurs when the tricuspid valve in your heart does not close all the way, usually because the valve has dilated, or stretched, and its leaflets don’t close tightly. This allows blood to flow backwards within the heart, and if severe may cause symptoms such as shortness of breath with activity and swelling in your abdomen, legs, or veins in your neck.
What is the TricValve® Transcatheter Bicaval system?
The TricValve® is an investigational device designed for the implantation of two dedicated self-expanding biological valves without the need for open-heart surgery. The valves are implanted using a minimally invasive delivery system where your doctor places a thin tube through a vein in your leg to reach your heart to position the self-expanding valves.
See how it works. Watch the TricValve procedural animation.
This trial is intended to evaluate the safety and effectiveness of the TricValve system with Optimal Medical Therapy (OMT) compared to OMT alone in patients with severe TR.
CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. This device is not available for marketing or commercial sale in the United States.
P & F USA, Inc. is the sponsor of the TRICAV-II Pivotal Trial.
DISCLAIMER: The material contained on this site is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Not all products are available for use in all countries. Always seek the advice of your physician or other qualified healthcare provider.